Starving liver cancer cells: new combo therapy aims to stop their 'Self-Eating' survival
NCT ID NCT05842174
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 28 times
Summary
This study tests whether adding a drug that blocks a cancer cell survival process (autophagy) to standard TACE treatment can better kill liver cancer cells and boost the immune system. About 93 adults with unresectable liver cancer will receive the combination. The goal is to see if this approach delays cancer progression longer than TACE alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
RECRUITINGPhiladelphia, Pennsylvania, 19104-4551, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.